Subscribe To
Alzheimer's medication: eisai reporting positive data on injectable drug
This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their Alzheimer's drug- Leqembi....
October 28, 2023, 9:00 am
: biogen and eisai release new alzheimer’s drug data that may support wider uptake
Eisai plans to apply for FDA approval of subcutaneous leqembi by early next year. Read Full Story The p...
October 25, 2023, 9:28 pm
Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...
October 25, 2023, 9:26 pm
Eisai presents new leqembi® (lecanemab-irmb) investigational subcutaneous formulation interim study results and clinical improvement data in earlier stages of early alzheimer’s disease from additional
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patien...
October 25, 2023, 9:26 pm
Biogen and eisai release new alzheimer's drug data that may support wider uptake
Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment leqembi that ...
October 25, 2023, 5:28 pm
Leqembi® intravenous infusion (lecanemab) approved for the treatment of alzheimer’s disease in japan
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...
September 25, 2023, 5:02 am
Japan approves alzheimer treatment leqembi by eisai and biogen
Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen....
September 25, 2023, 1:16 am
Biogen's (biib) stock outperforms industry ytd: here's why
While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like leqembi in Alzhe...
September 5, 2023, 11:18 am
Biogen to cut 1,000 jobs as focus turns to alzheimer's drug leqembi launch
Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat Alzheimer's di...
July 25, 2023, 1:35 pm
Biogen to cut roughly 11% of workforce
The biotech cited the launch of Alzheimer's drug leqembi as part of its new focus....
July 25, 2023, 9:26 am
Biogen to cut 1,000 jobs to save costs as company prepares for leqembi launch
Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025....
July 25, 2023, 8:39 am
All eyes on biogen's alzheimer's drug, a big potential payday, ahead of earnings
Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi....
July 24, 2023, 5:46 pm
Eli lilly & co study shows alzheimer's drug slows memory decline
Eli Lilly & Co revealed on Monday final results from its Phase 3 clinical study of donanemab at the Alzheimer's Association International Conference i...
July 17, 2023, 1:13 pm
Eli lilly expects fda decision on alzheimer's treatment donanemab by the end of the year
Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month....
July 17, 2023, 10:15 am
Why isn't biogen stock soaring after this major fda approval?
The FDA gave full approval for Alzheimer's drug leqembi in July. Despite the positive news, Biogen's st...
July 13, 2023, 8:15 am
Eisai to present the latest alzheimer's disease pipeline and research, including lecanemab and anti-mtbr tau antibody e2814, at the alzheimer's association international conference (aaic) 2023
TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the...
July 11, 2023, 7:30 pm
Eisai exec who helped steer alzheimer's drug approval to retire in july
The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment ...
July 11, 2023, 3:18 am
leqembi approval offers renewed hope for novel alzheimer's disease treatments
US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated w...
July 10, 2023, 4:43 pm
Biogen (biib) stock down despite fda nod to alzheimer's drug
Biogen (BIIB) stock falls despite leqembi getting the traditional nod for the treatment of Alzheimer's ...
July 10, 2023, 12:30 pm
Biogen shares ‘an under-owned turnaround story,' jefferies analysts say
Shares of Biogen Inc. BIIB, -3.48%, which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer's treatment Leqembi,...
July 10, 2023, 8:58 am